Schneider, Günter, Prof. Dr.

2003: Dr. med., University of Würzburg
1998-2002: Research Associate/Clinical Fellow, University of Ulm
since 2021: Professorship “Translational Cancer Research”, University Medical Center Göttingen, Department of General, Visceral and Pediatric Surgery

Major Research Interests

Our laboratory aims to understand molecular mechanisms that control therapeutic vulnerabilities of gastrointestinal cancers (e.g. pancreatic cancer, rectal cancer). Hereby, we intend to bridge pre-clinical and clinical cancer science to improve cancer treatment.

Homepage Department/Research Group
https://chirurgie-goettingen.de/forschung/ag-schneider

Selected Recent Publications

C. Falcomatà, S. Bärthel,…, G. Schneider*, D. Saur*. Genetic screens identify a context-specific PI3K/p27Kip1 node driving extrahepatic biliary cancer. Cancer Discovery (2021). DOI: 10.1158/2159-8290.CD-21-0209 * equally contributing senior authors

C. Falcomatà, S. Bärthel, …, G. Schneider, D. Saur. Combinatorial high throughput drug screening identifies a synergistic drug interaction that sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade. Nature Cancer (2021). accepted manuscript.

G. Schneider, M. Wirth, U. Keller, D. Saur. Rationale for MYC Imaging and Targeting in Panceratic Cancer. EJNMMI Research (2021). 11:104.

K. Lankes, Z. Hassan, M.J. Doffo, C. Schneeweis, S. Lier, R. Öllinger, R. Rad, O.H. Krämer, U. Keller, D. Saur, M. Reichert, G. Schneider*, M. Wirth*. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Molecular Oncology (2020) 14:3048-3064. * equally contributing senior authors

A. Biederstädt, Z. Hassan, C. Schneeweis, M. Schick, …, G. Schneider*, U. Keller*, SUMO Pathway Inhibition Targets an Aggressive Pancreatic Cancer Subtype. GUT (2020) 69:1472-1482. * equally contributing senior authors